Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Satellos Bioscience, Inc.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07287189CT.gov Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | — | Recruiting | — | — | — |
NCT06867107CT.gov An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 | — | Enrolling By Invitation | — | — | — |
NCT06565208CT.gov First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Duchenne Muscular Dystrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sat-3247 (this asset) | Satellos Bioscience, Inc. | P2 | B · 58 |
| Viltolarsen | NS Pharma, Inc. | P4 | BBB |
| Aoc 1044 | Avidity Biosciences, Inc. | P3 | BB |
| Delandistrogene Moxeparvovec | Sarepta Therapeutics, Inc. | P3 | BB |
| Golodirsen | Rare Disease Research, LLC | P4 | BB |
| Prednisolone | Anne M. Connolly | P4 | BB |
| Eteplirsen | Sarepta Therapeutics, Inc. | P3 | BB |
| Glutamine | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Casimersen | Kevin Flanigan | P3 | BB |
+41 more in the Duchenne Muscular Dystrophy cohort
Other indications for Sat-3247
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuromuscular Disease | — | P2 | CCC · 53 |
| Muscular Dystrophy | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sat-3247 in Duchenne Muscular Dystrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sat-3247-duchenne-muscular-dystrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →